Corbus Pharmaceuticals
CRBP
98 hedge funds and large institutions have $90.6M invested in Corbus Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 20 increasing their positions, 32 reducing their positions, and 28 closing their positions.
230% more call options, than puts
Call options by funds: $4.91M | Put options by funds: $1.49M
3% more capital invested
Capital invested by funds: $88.4M → $90.6M (+$2.22M)
0.15% more ownership
Funds ownership: 1.17% → 1.32% (+0.15%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8% less funds holding
Funds holding: 107 → 98 (-9)
32% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 28
38% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 32
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EMG
ETF Managers Group
Summit,
New Jersey
|
+$15M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.07M |
| 3 |
Mirae Asset Global Investments
Seoul,
South Korea
|
+$2.76M |
| 4 |
Millennium Management
New York
|
+$2.3M |
| 5 |
IEFM
IQ EQ Fund Management
Dublin 2,
Ireland
|
+$1.34M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$6.13M |
| 2 |
Morgan Stanley
New York
|
-$2.53M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
-$2.34M |
| 4 |
State Street
Boston,
Massachusetts
|
-$2.21M |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$1.08M |
CRBP Hedge Fund Activity: Q2 2021 in Review
98 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q2 2021, worth a combined $90.6M — up 2.5% from $88.4M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of CRBP and 19 opened new positions — a net loss of 9 holders — while 32 trimmed existing stakes and 20 added.
The largest buyer was ETF Managers Group, adding an estimated $15M. The largest seller was BlackRock, cutting an estimated $6.13M.
- 98 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q2 2021, down from 107 in Q1 2021.
- Funds reported $90.6M of Corbus Pharmaceuticals stock for Q2 2021, up 2.5% quarter-over-quarter.
- 19 funds opened new Corbus Pharmaceuticals positions in Q2 2021 and 28 closed out, a net change of -9 holders.
- The largest Corbus Pharmaceuticals buyer in Q2 2021 was ETF Managers Group, an estimated $15M added.
- The largest Corbus Pharmaceuticals seller in Q2 2021 was BlackRock, an estimated $6.13M sold.
Based on aggregated 13F filings for Q2 2021.